Exploring the next generation of antibody–drug conjugates

Tumour heterogeneity and resistance to cancer therapies

Dagogo-Jack, I., & Shaw, A. T. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2017.166 · Cited by 3,846

PROTAC targeted protein degraders: the past is prologue

Békés, M., Langley, D. R., & Crews, C. M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00371-6 · Cited by 3,395

Strategies and challenges for the next generation of antibody–drug conjugates

Beck, A., Goetsch, L., Dumontet, C., & Corvaïa, N. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.268 · Cited by 2,271

Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia

Kantarjian, H. M., Stein, A. S., Gökbuget, N., Fielding, A. K., Schuh, A. C., Ribera, J., Wei, A. H., Dombret, H., Foà, R., Bassan, R., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1609783 · Cited by 2,204

STING-Dependent Cytosolic DNA Sensing Mediates Innate Immune Recognition of Immunogenic Tumors

Woo, S.-R., Fuertes, M. B., Corrales, L., Spranger, S., Furdyna, M. J., Leung, M. Y. K., Duggan, R., Wang, Y., Barber, G. N., Fitzgerald, K. A., et al. (2014) · Immunity · doi:10.1016/j.immuni.2014.10.017 · Cited by 1,917

Prodrugs: design and clinical applications

Rautio, J., Kumpulainen, H., Heimbach, T., Oliyai, R., Oh, D.-M., Järvinen, T., & Savolainen, J. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2468 · Cited by 1,681

Site-specific conjugation of a cytotoxic drug to an antibody improves the therapeutic index

Junutula, J. R., Raab, H. E., Clark, S., Bhakta, S., Leipold, D. D., Weir, S., Chen, Y., Simpson, M., Tsai, S. P., Dennis, M. S., et al. (2008) · Nature Biotechnology · doi:10.1038/nbt.1480 · Cited by 1,388

Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations

Seidel, J. A., Otsuka, A., & Kabashima, K. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00086 · Cited by 1,360

DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1

Ogitani, Y., Aida, T., Hagihara, K., Yamaguchi, J., Ishii, C., Harada, N., Soma, M., Okamoto, H., Oitate, M., Arakawa, S., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2822 · Cited by 1,228

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209

Engineering antibody–drug conjugates targeting an adhesion GPCR, CD97

Hattori, T., Wang, M. Y., Corrado, A. D., Gross, S., Fang, M., Bang, I., Roy, N., Berezniuk, I., Donaldson, H., Groff, K. J., et al. (2025) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2516627122 · Cited by 3

Pathology, molecular biology, medical oncology, and radiotherapy implications of lung neuroendocrine neoplasm classification: a multidisciplinary perspective

Pelosi, G., Laffi, A., Catalano, G., Bruno, A., Papotti, M. G., Bassani, B., Bianchi, F., Duregon, E., Pas, T. M. D., Catania, C., et al. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2584486 · Cited by 3

Engineered virus-hunter vaccine overcomes HBV immune tolerance

Chen, X., Liu, X., Xu, T., Wang, Y., Wang, P., Liu, H., Jiang, Y., Qin, X., Zhang, L., Xiong, Y., et al. (2025) · Gut · doi:10.1136/gutjnl-2025-335806 · Cited by 3

Pd-Catalyzed Asymmetric Allylic Alkylation of Carboxylic Acids for the Synthesis of Chiral Butenolidyl Ester Prodrugs and Peptide–Drug Conjugates

Ma, Y., Ren, W., Song, C., Xu, G.-Q., & Kong, D. (2025) · Organic Letters · doi:10.1021/acs.orglett.5c04479 · Cited by 3

Antibody drug conjugates in Alzheimer’s disease: emerging strategies and future directions

AmeliMojarad, M., & AmeliMojarad, M. (2025) · Neuroscience · doi:10.1016/j.neuroscience.2025.12.053 · Cited by 3

Multiple protease-activated probody-drug conjugates for treating CD147-positive ovarian cancer with limited toxicity

Wang, B., Zhang, Q., Yang, Y., Wang, C., Deng, G., Chen, Y., Xu, Z., Zhinan, C., Zhou, C., & Zhang, S. (2026) · Pharmacological Research · doi:10.1016/j.phrs.2026.108120 · Cited by 3

Molecular glue degraders: Rational design, specificity engineering, and advanced delivery

Ma, L., Wang, N., Zhu, J., Wu, L., He, S., & Zhang, B. (2026) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2026.02.020 · Cited by 5

Biomarker-Guided Drug Delivery Systems and Oral Bioavailability Enhancement

Vo, D.-K., & Duong, V. (2026) · Pharmaceuticals · doi:10.3390/ph19030454 · Cited by 3

B7-H4: a multifaceted immune checkpoint and oncoprotein in cancer biology and immunotherapy

Zhang, C., Miao, Z., Cao, J., Wang, X., & Shi, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1837397 · Cited by 3

Orthogonal Conjugation via Endoglycosidase and Microbial Transglutaminase Enables Efficient Synthesis of Dual-Payload Antibody-Drug Conjugates

Yun, H., Gomozkova, M., Li, A., Zong, G., Nemes, P., & Wang, L. (2026) · ACS Chemical Biology · doi:10.1021/acschembio.6c00229 · Cited by 3

Targeted delivery of proteolysis-targeting chimeras (PROTAC) and molecular glue degraders (MGD)

Banerjee, M., Detappe, A., & Lammers, T. (2026) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2026.115922 · Cited by 4

Design, synthesis and bioactivity evaluation of novel monomethyl auristatin F analogues

Yang, L., Li, X., Zhao, L. Q., Hu, W., & Qian, Y. (2024) · Molecular Diversity · doi:10.1007/s11030-024-10873-1 · Cited by 3

GrB-Fc-KS49, an anti-EMP2 granzyme B fusion protein therapeutic alters immune cell infiltration and suppresses breast cancer growth

Mohamedali, K. A., Aguirre, B., Lu, C.-H., Chandla, A., Kejriwal, N., Liu, L., Chan, A. M., Cheung, L. H., Kok, S.-Y., Duarte, S. M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-008891 · Cited by 3

Surrogate endpoints for overall survival in randomized clinical trials testing antibody-drug conjugates

Pala, L., Merlo, F., Sala, I., Pagan, E., Oriecuia, C., Specchia, C., Catania, C., Cocorocchio, E., Laszlo, D., Ceresoli, G. L., et al. (2025) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djaf049 · Cited by 4

Design, Construction, and Validation of a Yeast-Displayed Chemically Expanded Antibody Library

Rezhdo, A., Hershman, R. L., Williams, S. J., & Deventer, J. A. V. (2025) · ACS Synthetic Biology · doi:10.1021/acssynbio.4c00421 · Cited by 3

Unlocking the potential of engineered microbes in immunotoxin-based cancer therapy

Wang, Q., Cao, R., Xie, Y., Zhang, Z., Li, X., Zhang, Y., Luo, H., Yao, H., Xue, P., & Ni, S. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1603671 · Cited by 3

QSP modeling of loncastuximab tesirine with T-cell-dependent bispecific antibodies guides dose-regimen strategy

Li, Y., Wilkins, A. K., Davis, J. L., Knab, T., Toukam, M., Boni, J. P., & Kirouac, D. C. (2025) · npj Systems Biology and Applications · doi:10.1038/s41540-025-00544-8 · Cited by 3

Tubulin inhibitors: an insight into new strategies to combat leukemia

Verma, S., Gupta, P., Narang, R., Lal, S., & Singh, V. (2025) · Future Medicinal Chemistry · doi:10.1080/17568919.2025.2546774 · Cited by 3

The evolving landscape of antibody-drug conjugates in small cell lung cancer: From research progress to clinical application

Wang, H., Zhang, C., & Wang, H. (2025) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2025.189445 · Cited by 3

A QSP PDE model of ADC transport and kinetics in a growing or shrinking tumor

Ross, D. S., & Cabal, A. (2025) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-025-10001-y · Cited by 3

Proteolysis activity mapping and substrate discovery platform for identifying tumor-activated biosensors

Algov, I., Heest, A. E. V., Hopton, M., Liang, F., Holmes, A., Hao, L., & Zhou, X. X. (2026) · Nature Chemical Biology · doi:10.1038/s41589-026-02218-w · Cited by 5

Antibody-Drug Conjugates of NLRP3 Agonists: How Overcoming Lysosomal Accumulation Necessitated Noncanonical Linker Attachments

Riehl, P. S., Zhang, M. Y., Dhar, P., Wang, Z., Pan, J., Mansfield, K. D., Johnson, W. L., Zhang, Q., Li, Y., D’Souza, R., et al. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00596 · Cited by 3

Chemical Process Development in the Pharmaceutical Industry in Europe—Insights and Perspectives from Industry Scientists

Krueger, J., Dieskau, A. P., Hassfeld, J., Gries, J., Block, O., Weinmann, H., Kaufmann, D., Hildbrand, S., Kraft, V., Moeckel, R., et al. (2025) · Angewandte Chemie · doi:10.1002/ange.202420719 · Cited by 3

Evaluation of the implementation effectiveness of accelerated drug marketing registration procedures in China: lessons from the 2016–2024 regulatory review

Lan, Y., Li, W., Lin, X., Wu, Y., & Huang, Z. (2025) · Drug Discovery Today · doi:10.1016/j.drudis.2025.104353 · Cited by 2

Antibody–Drug Conjugate Stability Probed by Variable-Temperature Electrospray Ionization Mass Spectrometry

Fiala, J., Schuster, D., & Heck, A. J. R. (2025) · Journal of the American Society for Mass Spectrometry · doi:10.1021/jasms.5c00109 · Cited by 2

Deuterium substitution at the intolerable site as a strategy to mitigate the toxicity of camptothecin derivatives

Yu, X., Sun, Z., Liu, J., Huangfu, S., Cheng, Q., Chen, J., Yang, X., Jiang, B., & Chen, H. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.117877 · Cited by 2

Therapeutic potential, formulation strategies and cancer treatment applications of ripe papaya pectin (Carica papaya L.): A comprehensive review

Wagh, H., & Bhattacharya, S. (2025) · Carbohydrate Polymer Technologies and Applications · doi:10.1016/j.carpta.2025.100942 · Cited by 3

Immune cell transcriptional profiles from pre-vaccination peripheral blood predict immune response to preventative MUC1 cancer vaccine

Yuan, D. Y., McKeague, M. L., Raghu, V. K., Schoen, R. E., Finn, O. J., & Benos, P. V. (2025) · European Journal of Cancer · doi:10.1016/j.ejca.2025.115685 · Cited by 3

NIR‐Activatable, Sequence‐Specific Metal‐Nucleic Acid Scaffolds for Responsive Uncaging

Sharma, A., Kshetri, M. B., Karna, D., Amin, M. A., Akter, S., Mao, H., & Zheng, Y. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202514717 · Cited by 2

Antibody-DNA nanostructure conjugates exhibit inhibited effects on CT26 cells and prevent upregulation of PD-1 in the tumor microenvironment

Li, C., Chen, F., Wu, J., Ren, J., Li, Y., Li, S., & Xia, Z. (2025) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2025.148101 · Cited by 4

Antibody drugs conjugates in small-cell lung cancer: present-day status and promises

Syal, A., Meyer, M., Angelino, K. L., Osei, N., Gomez, J. E., Hirsch, F. R., & Sen, T. (2025) · The Oncologist · doi:10.1093/oncolo/oyaf332 · Cited by 2

Towards a glutathione-cleavable azobenzene linker for antibody–drug conjugates

Kapun, M., Patel, R. A., Park, M., Pérez-Areales, F. J., Kostadinova, K. A., Wharton, T., Carroll, J. S., & Spring, D. R. (2025) · Chemical Communications · doi:10.1039/d5cc05824d · Cited by 2

NQO1-responsive Trimethyl lock benzoquinone: A cleavable linker strategy for antibody-drug conjugates

Wang, Z., Liu, K., Shang, C., Yan, X., Dong, Y., Li, D., Li, Y., Zhang, C., Ren, W., Ma, C., et al. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.114534 · Cited by 2

Bottom–Up Protein Analysis Workflow for Simultaneous Characterization of Payloads, Disulfide Bonds, and Free Thiols in Antibody–Drug Conjugates

Zhou, K., & Xia, Y. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c05683 · Cited by 2

The glycosaminoglycan oncofetal chondroitin sulfate is a novel target for antibody-drug conjugate therapy for AML

Mujollari, J., Estruch, M., Khadgawat, P., Choudhary, S., Gustavsson, T., Dagil, R., Redlinger, N., Løppke, C., Vidal-Calvo, E. E., Nordmaj, M. A., et al. (2025) · Blood · doi:10.1182/blood.2024028147 · Cited by 2

Dipiperazine‐Phenyl Derivatives Based on Convergent Molecular Platforms Can Reverse Multidrug Resistance in Gram‐Negative Bacteria by Inhibiting Efflux and Permeabilizing Cell Membranes

Dong, J., Guo, T., Huang, Y., Ma, Y., Chen, W., Xue, J., Jiang, J., Dong, E., Kong, Y., Ding, H., et al. (2026) · Advanced Science · doi:10.1002/advs.202512859 · Cited by 3

Bench-to-Bedside Perspectives on Ocular Toxicity of Antibody–Drug Conjugates: Toxicology, Clinical Management and Molecule Optimization

Zhang, J., Li, W., Li, M., Wu, G., Ni, Y., Du, J., Xu, G., Duan, M., Yang, Y., Yu, X., et al. (2026) · Pharmaceutical Research · doi:10.1007/s11095-025-03953-w · Cited by 3

Progress in targeting the untouchables: emerging approaches for hard-to-drug cancer targets

Coleman, N., Tan, H., & Rodon, J. A. (2026) · Annals of Oncology · doi:10.1016/j.annonc.2026.01.012 · Cited by 2

Trop2-Based Antibody–Drug Conjugates: Emerging Strategy and Progress in Triple-Negative Breast Cancer Therapy

Li, T., Zhang, T., Dang, Y., Lin, Y., Li, X., & Ling, X. (2026) · Current Oncology · doi:10.3390/curroncol33020092 · Cited by 2

Antibody–drug conjugates in colorectal cancer: advances in targeted delivery and personalized oncology

Wang, H., Yan, X., Xia, C., Chen, D., Pan, B., Zhang, Y., & Zhang, Q. (2026) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2026.1756741 · Cited by 2

Focusing on toxicity management: Challenges and strategies for HER2-targeted antibody–drug conjugates in breast cancer

Liu, X., Yin, S., Li, X., & Nie, J. (2026) · The Breast · doi:10.1016/j.breast.2026.104741 · Cited by 5

Supramolecular coiled-coil peptide platform for site-specific antibody drug conjugate engineering

Ringaci, A., Shih, T., & Grinstaff, M. W. (2026) · Nature Communications · doi:10.1038/s41467-026-70094-y · Cited by 2

Reprogramming the tumor immune microenvironment via antibody-drug conjugates

Xu, T., Gu, Y., & Guan, X. (2026) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2026.2642215 · Cited by 2

Selective fluorination of Fc glycans enhances antibody-mediated effector functions

Wang, X., Gomozkova, M., Li, S., Banerjee, B. N., Zong, G., Missiakas, D. M., & Wang, L. (2026) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2530653123 · Cited by 2

Advances in Antibody Engineering for Therapeutic Development: Molecular Strategies and Clinical Applications

Akinsulie, O. C., Ulusan, S., Idris, I., Shahzad, S., Okon, J., Ukauwa, C. B., Oladoye, M. J., Aliyu, V. A., Ugwu, C. E., Ayandokun, T. F., et al. (2026) · Immuno · doi:10.3390/immuno6020023 · Cited by 2

Comprehensive evaluation of the analytical toolbox for commercial cysteine-linked antibody-drug conjugates

Wagner, E., Maurer, J., Zanna, L., Colas, O., Humbert, A., Guillarme, D., & Haeuw, J. (2026) · Journal of Chromatography A · doi:10.1016/j.chroma.2026.466966 · Cited by 2

EGFR-targeted therapies based on antibody engineering and nanotechnology for colorectal cancer

Shang, X., Zhang, Z., Wu, T., Nan, Y., & Ju, D. (2026) · Biomaterials · doi:10.1016/j.biomaterials.2026.124210 · Cited by 3

In-depth Characterization of Photo-Stressed Antibody–Drug Conjugates by Mass Spectrometry

Pan, X., Zhao, Y., Luo, S., Bulos, J., Zhong, J., Yan, Y., Wu, Z., Su, Y., Zhang, S., Wang, S., et al. (2026) · The AAPS Journal · doi:10.1208/s12248-026-01247-6 · Cited by 2

Novel photoactive agents based on phthalocyanines conjugated to targeting vectors: trends and challenges

Vorobyov, I. I., Fedorov, A. Y., & Gorbunova, Y. G. (2026) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2026.218101 · Cited by 4

Antibody-drug conjugates in recurrent or metastatic HNSCC: relevant targets, clinical development, and future prospects

Zhao, H., Zhang, S., Wang, F., Yu, P., Li, J., Jia, L., He, P., Liu, R., Zhang, J., Wang, K., et al. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1828131 · Cited by 2

Overcoming Primary and Acquired Resistance to Immunotherapy in Non–Small Cell Lung Cancer: Mechanisms, Challenges, and Emerging Strategies

Hidalgo-Filho, C. M., Santo, V., Gariazzo, E., Aldea, M. D., Pecci, F., Danlos, F., Junior, G. D. C., & Ricciuti, B. (2026) · Journal of Clinical Oncology · doi:10.1200/jco-25-03026 · Cited by 2

Antibody–drug conjugates in colorectal cancer: molecular design, preclinical advances, and translational challenges

Ansari, M. A., Abubakar, M., Ansari, M. M., Koya, N., Gupta, J., Aazam, M., Shinde, S. S., Ahmed, S., Rai, A., Murti, K., et al. (2026) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-026-04906-9 · Cited by 2

Pancancer pro-angiogenic atlas unravels tumor-educated pericyte-augmented anti-angiogenic resistance

Zheng, Y., Sun, H., Fu, Z., Chen, H., Cai, G., Huang, X., Pan, Y., Yu, K., Chen, P., Liang, Z., et al. (2026) · 中国科学通报：英文版 · doi:10.1016/j.scib.2026.06.022 · Cited by 2

Antibody–drug conjugates in non-small cell lung cancer: current landscape and future directions

Chen, X., Wu, S., Li, F., Yao, C., Liu, Y., & Zhou, G. (2026) · Holistic Integrative Oncology · doi:10.1007/s44178-026-00276-7 · Cited by 2

Linker Design in Antibody-Drug Conjugates: Balancing Stability and Drug Release

Albino, S. N., Domingos, M. M., Pacheco, T. R., Carvalho, A., Castanho, M. A. R. B., & Cavaco, M. C. (2026) · Pharmaceutics · doi:10.3390/pharmaceutics18080954 · Cited by 2

Chemically Programmed Fc Protein as Antibody Mimetic to Targeting Carbonic Anhydrase IX

Wang, H., Song, J., Quan, Y., Liu, J., & Tai, W. (2024) · Bioconjugate Chemistry · doi:10.1021/acs.bioconjchem.4c00259 · Cited by 2

Programmable Circular Multivalent Nanobody‐Targeting Chimeras (mNbTACs) for Multireceptor‐Mediated Protein Degradation and Targeted Drug Delivery

Jiang, S., Lv, X., Ouyang, Z., Chi, H., Zeng, Y., Wang, Y., He, J., Chen, J., Chen, J., An, K., et al. (2024) · Angewandte Chemie · doi:10.1002/ange.202407986 · Cited by 2

Photocatalytic Multiple Deuteration of Polyethylene Glycol Derivatives Using Deuterium Oxide

Ogasahara, R., Mae, M., Matsuura, K., Yoshimura, S., Ishimoto, T., Udagawa, T., Harada, K., Fujioka, H., Kamiya, M., Asada, R., et al. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202404204 · Cited by 2

Synthesis and evaluation of KX-01 analogs with an exploration of linker attachment points for antibody-drug conjugates

Oh, Y., An, D. E., Park, J., Koh, B., Cho, K., & Jeon, H. (2025) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2025.130114 · Cited by 2

HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials

Wang, X., Zhao, L., Gao, F., Meng, Y., Yang, J., Zhu, M., Liao, D., Jia, Y., & Kong, F. (2025) · Current Medicinal Chemistry · doi:10.2174/0109298673358929250213093803 · Cited by 2

Photocatalyzed elaboration of antibody-based bioconjugates

Stum, M. L., Romero, E., & Molander, G. A. (2025) · Beilstein Journal of Organic Chemistry · doi:10.3762/bjoc.21.49 · Cited by 2

Oncology: What You May Have Missed in 2024

Maqrashi, Z. A. A. A., Chan, S. W. S., Siddiqui, Z., & Dotan, E. (2025) · Annals of Internal Medicine · doi:10.7326/annals-25-00963 · Cited by 2

Insights from the bottom-up development of LGR5-targeting immunotherapeutics

Mueller, N., de la Roche, M., & de la Roche, M. (2024) · Immunotherapy Advances · doi:10.1093/immadv/ltaf017 · Cited by 2

Clinical trial landscape of lung cancer treatment with ADCs: current perspectives and future directions

He, Y., Huang, W., Hong, H., Li, Y., Shen, Y., & Qu, Y. (2025) · International Journal of Surgery · doi:10.1097/js9.0000000000002501 · Cited by 2

Auristatin S: An Auristatin Payload with Improved Tolerability and Modified Bystander Activity

Moquist, P. N., Eng-Duncan, N. M.-L., Bovee, T. D., Snead, K., Bou, L., Zhang, X., Blackburn, B., Wright, J. A., Simmons, J. K., Neff‐LaFord, H. D., et al. (2025) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.5c00238 · Cited by 2

Clinical pharmacologic considerations for antibody-drug conjugate in gynecologic cancers

Ettorre, V. M., Palmieri, L., & Santin, A. D. (2025) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2025.2535178 · Cited by 2

Ocular Adverse Events of Antibody Drug Conjugates and Association With Survival From a Real-World Database

Kim, S. H., Marshall, R. F., Wai, K. M., Rahimy, E., Vingopoulos, F., Mishra, K., Berkenstock, M., & Mruthyunjaya, P. (2025) · Cornea · doi:10.1097/ico.0000000000003997 · Cited by 2

Improved Access to Potent Anticancer Tubulysins and Linker‐Functionalized Payloads Via an All‐On‐Resin Strategy

Ricardo, M. G., Llanes, D., Rennert, R. C., Jänicke, P., Rivera, D. G., & Wessjohann, L. A. (2024) · Chemistry - A European Journal · doi:10.1002/chem.202401943 · Cited by 2

Modifying platelets at their birth: anti-thrombotic therapy without haemorrhage

Feely, C., Kaushal, N., D’Avino, P. P., & Martin, J. F. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1343896 · Cited by 1

Determination of the decapping efficiency of THIOMAB™ antibodies with the engineered cysteine in the Fc region for making antibody–drug conjugates by specific hinge fragmentation-liquid chromatography

Yang, Y., Patel, J. M., Yang, R., Ma, F., Niu, X., Zhang, Y., Niedringhaus, T. P., Al-Sayah, M., & Yang, X. (2024) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-024-05707-w · Cited by 1

Direct Preparation of Site‐Specific Antibody–Drug Conjugates with Unpurified Antibodies in Culture Medium

Lu, M., Zeng, Y., Hang, J., Shi, W., Huang, W., & Tang, F. (2025) · ChemBioChem · doi:10.1002/cbic.202401082 · Cited by 2

Research progress of antibody coupling technique in targeted drug delivery

Li, M., Wang, T., Tan, D., Wang, M., Lei, C., Wang, Y., & Hu, S. (2025) · Interdisciplinary medicine · doi:10.1002/inmd.20240108 · Cited by 1

Payloads of Antibody: Drug Conjugates

Tan, C. (2025) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-83005-1_2 · Cited by 2

Systemic study on anti-tumor activity of HER2 induced peptide-drug conjugate clustering in xenograft tumor models

Chen, Q., Hou, D., Zhang, N., Wang, J., Zheng, R., Hu, X., Wu, X., Yi, L., Zhang, Y.-J., Zhang, G., et al. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.111257 · Cited by 1

CD33-D2 isoform characterization for advancement of its therapeutic potential

Shastri, V. M., Madabushi, S. S., Hui, S. K., & Lamba, J. K. (2025) · Immunotherapy · doi:10.1080/1750743x.2025.2493038 · Cited by 1

Design of heavy chain antibody-drug conjugates targeting c-Met to eradicate lung adenocarcinoma giant tumors with a single-dose

Ning, W., Liu, H., Zeng, H., Qin, X., Xu, L., Yang, S., Zeng, Z., Yuan, N., Zhu, Z., Chen, X., et al. (2025) · 中国科学通报：英文版 · doi:10.1016/j.scib.2025.04.066 · Cited by 1

Accelerating biotherapeutics discovery: Blueprint for a universal LC-MALDI-MS offline approach

Bayne, E. F., Gao, X.-Z., Jiang, Y., Bennett, R., Regalado, E. L., Pirrone, G. F., & Makarov, A. A. (2025) · Analytica Chimica Acta · doi:10.1016/j.aca.2025.344312 · Cited by 1

RC48 Induces Senescence in HER2-Expressing Colon Cancer Cells by Activating the CDKN1A-RB-E2F1 Pathway

Wu, J., Li, Q., Cheng, X., Dai, C., Huang, Q., & Wang, Y. (2025) · Current Cancer Drug Targets · doi:10.2174/0115680096388633250704101500 · Cited by 1

Mechanistic modeling suggests stroma-targeting antibody-drug conjugates as an alternative to cancer-targeting in cases of heterogeneous target exspression

Wood, N. E., Cengiz, A., Gao, M., Ratushny, A. V., & Straube, R. (2025) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1012839 · Cited by 1

Advances in Techniques for the Structure and Functional Optimization of Therapeutic Monoclonal Antibodies

He, C., Huang, W., Wu, X., & Xia, H. (2025) · Biomedicines · doi:10.3390/biomedicines13092055 · Cited by 1

A Self‐Assembled Protein Platform for Plug‐and‐Play Customization of Multivalent Artificial Antibodies and Antibody‐Drug Conjugates

Chen, Y., Huang, Y., Wang, S., Wang, X., Lu, H., Chen, J., Li, J., Chen, Z., Zhao, L., She, T., et al. (2025) · Angewandte Chemie International Edition · doi:10.1002/anie.202506426 · Cited by 1

Iron (III) triflate catalyzed, one-pot three-component synthesis of novel α-aminophosphonate of 5-hydrazineyl-2-(phenylsulfonyl)pyridine as potent antiproliferative agents against MCF-7 and HCT-116: In vitro and in silico investigations on molecular docking and dynamics simulation

Aljohani, G. F. (2025) · Arabian Journal of Chemistry · doi:10.25259/ajc_241_2025 · Cited by 1

A cytotoxic peptide-drug conjugate for tumor-specific delivery of co-injected molecules

Miyamura, N., Yamazaki, C. M., Anami, Y., Tsuchikama, K., & Sugahara, K. N. (2025) · PLoS ONE · doi:10.1371/journal.pone.0331564 · Cited by 1

Peptide/Antibody–Drug Conjugates for Therapeutic Applications in Inflammatory Disease

Jang, Y., Choi, J., Ryu, Y., Song, H. K., Shim, M. K., & Yang, Y. (2025) · Advanced NanoBiomed Research · doi:10.1002/anbr.202500150 · Cited by 1

Genetic Code Expansion-Driven in Situ Click Labeling Enables Rapid Imaging-Based Selection of Functional Nanobody–Dye Conjugates

Seike, N., Kojima, R., Tachibana, R., Fujita, K., Yanagisawa, T., Yokoyama, S., & Urano, Y. (2025) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c25-00376 · Cited by 1

Tumor–Immune Interactions in Pediatric Oral Rhabdomyosarcoma: A Narrative Review on Immuno-Oncology and Emerging Therapies

Meligy, O. E., Elemam, N. M., Hassan, W. A., & Talaat, I. M. (2025) · Children · doi:10.3390/children12091249 · Cited by 1

Introduction to the Immune System

McComb, S., Thiriot, A., Akache, B., Krishnan, L., & Stark, F. C. (2025) · Methods in molecular biology · doi:10.1007/978-1-0716-4832-2_1 · Cited by 1

Magnetic Resonance Imaging Using a Chimeric Anti-Glypican-3 Antibody Conjugated with Gadolinium Selectively Detects Glypican-3-Positive Hepatocellular Carcinoma In Vitro and In Vivo

Liu, Y., Tan, M., Chua, M., & So, S. K. (2025) · Cancers · doi:10.3390/cancers17203357 · Cited by 1

Meflin is a druggable target using antibody-drug conjugates in progressive osteosarcoma

Esaki, N., Sakoda, T., Ando, R., Miyai, Y., Iida, T., Mizutani, Y., Yoshida, M., Hara, Y., Matsuyama, M., Kobayashi, T., et al. (2025) · Oncogene · doi:10.1038/s41388-025-03605-8 · Cited by 1

HRA00129-C004, a Novel c-Met Antibody–Drug Conjugate, Exerts Encouraging Antitumor Activities and Favorable Safety Profiles

Tian, Y., Zhang, J., Sun, X., Yang, C., & Liao, C. (2025) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-24-0680 · Cited by 1

Assessment of ADC Higher Order Structure Through 2D NMR Analysis

Grasso, E. M., Marquard, A. N., Sparta, Z., Fry, D., & Jain, N. F. (2025) · Molecules · doi:10.3390/molecules30224490 · Cited by 1

Comparative analysis of therapeutic target protein expression in de novo and transformed small cell lung carcinomas using paired biopsy samples

Murata, S., Kashima, J., Horinouchi, H., Kishikawa, S., Masuda, K., Shinno, Y., Okuma, Y., Yoshida, T., Goto, Y., Yamamoto, N., et al. (2026) · Lung Cancer · doi:10.1016/j.lungcan.2026.109418 · Cited by 1

Preclinical Proof of Concept for the Single‐Protein Anticancer Molecule Targeting Both a Tumor Surface Antigen and an Intracellular Oncoprotein

Byun, K. T., Kim, B., Lee, I., Cho, J., Hwang, Y., Cheon, S. Y., Kang, H. C., Kim, C. G., Byun, J. W., Paeng, J. C., et al. (2025) · Advanced Healthcare Materials · doi:10.1002/adhm.202502786 · Cited by 1

What is on the Horizon Beyond Platinum and Immunotherapy for Patients With Advanced Non–Small Cell Lung Cancer Without Actionable Genomic Aberrations?

Rangel, A. R., Chagas, G. C. L., Chagas, R. C. L., & Osta, B. E. E. (2025) · JCO Oncology Practice · doi:10.1200/op-25-00936 · Cited by 1

HER2 Antibody–Nanogel Conjugates: A High-Capacity, Antibody-Sparing Alternative to Antibody–Drug Conjugates

Qiu, J., Alp, Y., Gong, S., Szipszky, P., Jerry, D. J., & Thayumanavan, S. (2025) · Nano Letters · doi:10.1021/acs.nanolett.5c04911 · Cited by 1

Bioanalytical Methodologies for Pharmacokinetic Characterization of Antibody Drug Conjugates

Xue, Y. J., Myers, M. V., Chen, J., Chen, M. J., Melo, B., Vallejo, M., Maxwell, S. E., Shen, J. X., Mora, J. R., & Surapaneni, S. (2026) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-031-89319-3_6 · Cited by 1

h3B7A-LDM, a novel anti-mesothelin antibody-drug conjugate with the potential to induce antitumor immunity, shows potent efficacy against solid tumors

Zhou, D., Xie, Z.-H., Duan, A.-J., Zhu, S.-Y., Wang, Y., Zhen, Y., Gao, R., & Miao, Q. (2026) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2026.101550 · Cited by 1

Development of Antibody–Drug Conjugates Targeting L1CAM to Treat Metastatic Cancer

Park, J. S., Kenum, C., He, L. Y., Khan, A. G., Pohl, M. A., White, T. E., Kodangattil, S. R., Rudin, C. M., Balderes, P. J., Lorenz, I. C., et al. (2026) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-25-1184 · Cited by 1

Exploiting intracellular oncogenic proteins to release cytotoxins

Schild, M., & Gillingham, D. G. (2026) · RSC Medicinal Chemistry · doi:10.1039/d5md00764j · Cited by 1

Multi-specific antibody drug conjugate: The next frontier for solid tumors

Hao, X., Wu, X., Yang, X., Guo, H., & Yang, R. (2026) · Chemical Engineering Journal · doi:10.1016/j.cej.2026.173329 · Cited by 1

Next Generation Antibody–Drug Conjugates: Molecular Design Innovations And Overcoming Resistance – A Comprehensive Review

Hari Nandhini.A, D. S. S. M. B. R. (2025) · Vascular and Endovascular Review · doi:10.64149/j.ver.8.16s.217-224

Antibody–Drug Conjugates: The Dynamic Evolution from Conventional to Next-Generation Constructs

Metrangolo, V., & Engelholm, L. H. (2024) · Cancers · doi:10.3390/cancers16020447 · Cited by 77

Antibody-drug conjugates in cancer therapy: current advances and prospects for breakthroughs

Wu, D., Yang, K., He, R., Yin, R., & Shui, L. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1669592 · Cited by 25

Antibody-drug conjugates: mechanism, progress and future directions of cancer targeted therapy

Li, M., Wu, G., Chen, B., Zheng, Z., Ning, X., Li, J., De, Z., Li, J., & Song, J. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02817-0

Unlocking the potential of antibody–drug conjugates for cancer therapy

Drago, J. Z., Modi, S., & Chandarlapaty, S. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00470-8 · Cited by 1,209